Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

NCT03116594 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.

NCT NCT03116594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
Lead sponsor
SK Chemicals Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
January 3, 2014
Completion date
March 7, 2015
Enrollment
675 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster